Navigation Links
Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment
Date:4/1/2008

LONDON, April 1, 2008 /PRNewswire/ -- Plethora Solutions Holdings PLC ("Plethora", AIM: PLE), the developer of specialist products for the treatment and management of urological disorders, today announced that it has entered into a revenue interest financing agreement with Paul Capital Healthcare. Through this agreement, Plethora will receive up to $28 million in cash with $15 million payable upon signature and a further $10 million upon first commercial sale of PSD502 (PLE's development stage product for the treatment of premature ejaculation) in the USA, subject to certain conditions. In return, Paul Capital Healthcare will receive an interest in the revenues generated from Plethora's male health portfolio. In addition, under certain pre-agreed conditions, Plethora will have the option to have Paul Capital Healthcare invest an amount of $3 million by way of equity subscription in 2008. The initial payment of $15 million will provide working capital to underwrite ongoing Phase III programmes in premature ejaculation and erectile dysfunction as well as strengthening the Plethora balance sheet to facilitate potential product and corporate transactions. Additional terms of the transaction are not disclosed.

The revenue interest will be paid by Plethora primarily on revenues derived from sales of ErecAid, PSD502 and PSD510. ErecAid is marketed by Plethora's subsidiary, Timm Medical, for the treatment of erectile dysfunction; while PSD502 and PSD510 are in Phase III clinical development for the treatment of premature ejaculation and erectile dysfunction respectively. Future revenues from the remainder of the existing Plethora portfolio for the treatment of female urological disorders are not covered under this agreement.

Alongside this transaction, Plethora has amended and expanded the existing convertible debt facility with ETV Capital S.A that the Company put in place in July 2007. As part of this revised arrangement, ETV Capital S.A. could potent
'/>"/>

SOURCE Paul Capital Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
2. Pharmasset Receives $10 Million of Working Capital
3. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
4. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
5. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum
6. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
7. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
8. AspenBio Pharma to Present at the Roth Capital Partners 20th Annual Growth Stock Conference
9. CryoLife to Present at Roth Capital Partners 20th Annual Orange County (OC) Growth Stock Conference
10. WaferGen to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
11. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 The report expects global cell ... 2019. It also provides a carefully analyzed data about ... for the market. , Full Copy of Report @ ... global market for cell expansion will keep witnessing growth ... this growth to be driven by rapid technological advancements, ...
(Date:12/24/2014)... 2014 China Biologic Products, Inc. (NASDAQ: ... fully integrated plasma-based biopharmaceutical company in ... subsidiary, Shandong Taibang Biological Products Co. Ltd., has ... China Food and Drug Administration (the "CFDA") for ... disclosed in the Company,s public filings, the CFDA ...
(Date:12/24/2014)... PharmaBoardroom,s new report, , ... available for free download , digs deep into this ... in the sector today. One area where ... in developing a homegrown pharmaceutical manufacturing base, even if the ... some way off. A cursory comparison with neighboring ...
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... - To better reflect its mission of funding ... used technological term, the Center for Technology Transfer in ... , ,The private, nonprofit organization provides investment funding ... energy-saving technologies, and need assistance to bring their products ...
... Madison, Wis. - Medical imaging technology provider GE ... new molecular imaging agent for the detection of cancer. , ... to track the process of angiogenesis, or the formation of ... to quantify therapy for Stage IV metastatic tumors in breast ...
... - As part of its $6 billion national effort, ... extend coverage to customers in Wisconsin and Illinois. , ... when Cingular invested more $300 million in the state and ... Wisconsin. , ,Since the start of 2006, nine cities have ...
Cached Biology Technology:
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... -- CIE San Diego has launched an innovative trust ... that enhances care coordination among social service and care ... earned a second $1 million grant from the Alliance ... in community and; will be recognized as a "Live ... 4-6p. CIE San Diego today announced the ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... role in the spread of disease and in the ... radical theories about nanobacteria ?micro-organisms considerably smaller than ordinary ... articles in the Journal of Proteome Research by Dr ... and Professor Chandra Wickramasinghe of Cardiff University, UK. , ...
... The first `next generation' MRI (magnetic resonance imaging) body scanner ... later this week (Friday 18 th February). , The Achieva ... Manchester and will be used by researchers to further their ... , The state-of-the-art technology involved will revolutionise the way scanning ...
... St. Louis have learned that a temporal "window of ... diabetic rats with embryonic pig tissues. , In those ... that they didn't have to give anti-rejection drugs to ... had expected rats that received no immune suppression would ...
Cached Biology News:Nanobacteria in clouds could spread disease, scientists claim 2Next Generation Body Scanner Launched By The University Of Manchester 2Next Generation Body Scanner Launched By The University Of Manchester 3Precise Timing Enabled Pig-to-rat Transplants To Cure Diabetes 2Precise Timing Enabled Pig-to-rat Transplants To Cure Diabetes 3
... a compact, versatile system that simultaneously harvests ... 24-well microplates into a solid filter supports ... and gamma counter. The FilterMate is ideal ... such as cell proliferation, receptor binding, nucleic ...
... base medium for preparation of minimal and synthetic ... does not contain amino acids. Both bulk and ... contains reagents to prepare 500 ml of 10X ... 10X YNB for S. cerevisiae media. Store at ...
... based screening project: , 384 ... 96 shape-diverse mixtures of 4 (5 uL each) , ... Individual compounds are dissolved in DMSO at ... Supplied in 5 96-well trays. Dilute library with ...
... Assay Kits are ideal for studying ... compounds using fluorescence polarization (FP) The ... glutathione transferase to the ligand binding ... and a proprietary, fluorescently-tagged progesterone ligand, ...
Biology Products: